High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis

Blood

Volumn 87, Issue 3, 1996, Pages 1155-1161

  Marks, David I ^b   Kurz, Benedikt W ^b   Link, Michael P ^b   Ng, Eliza ^b   Shuster, Jonathan J ^b   Lauer, Stephen J ^b   Brodsky, Isadore ^b   Haines, Dale S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CANCER RECURRENCE; CHILD; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RNA SYNTHESIS; TREATMENT PLANNING;

EID: 0030020462     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.1155.bloodjournal8731155     Document Type: Article

References (35)

1. Rivera GA, Crist WM: Acute lymphoblastic leukemia, in Handin RI, Lux SE and Stossel TP (eds): Blood - Principles and Practice of Hematology. Philadelphia, PA, Lippincott, 1995, p 743
2. Pui C-H: Childhood leukemias. N Engl J Med 332:1618, 1995
3. Crist WM, Carroll AJ, Shuster JJ, Behm FG. Whitehead M, Vietti TJ, Look AT, Mahoney D, Ragab A, Pyllen DJ, Land VJ: Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). Blood 76:117, 1990
4. Fletcher JA, Tu N, Tantravahi R, Sallan SE: Extremely poor prognosis of pediatric acute lymphoblastic leukemia with translocation (9;22): Updated experience. Leuk Lymphoma 8:75, 1992
5. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome - A Pediatric Oncology Group study. Blood 76:489, 1990
6. Reiter A, Schrappe M, Ludwig W-D, Lampert F, Harbott J, Henze C, Niemeyer CM, Gadner H, Müllerweihrich S, Riher J, Odenwald E, Riehm H: Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 80:2471, 1992
7. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
8. Wada M, Bartram CR, Nakamura H, Hackiya M, Chen D-L, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP: Analysis of p53 mutations in a large series of lymphoid malignancies of childhood. Blood 82:3163, 1993
9. Dicciani MB, Yu J, Hsiao M, Mukherjee S, Shao L-E. Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105, 1994
10. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523, 1992
11. Quesnel B, Preudhomme C, Oscier D, Lepelley P, O'Hooghe MC, Facon T, Zandecki M, Fenaux P: Over-expression of the mdm-2 gene is found in some cases of haematological malignancies Br J Haematol 88:415, 1994
12. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617, 1993
13. Zhou M, Yeager AM, Smith SD, Findley HW: Overexpression of the mdm2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85:1608, 1995
14. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
15. Vidal-Puig A, Moller DE: Comparative sensitivity of alternative single strand conformation polymorphism methods. Biotechniques 17:490, 1994
16. Spinardi L, Mazars R, Theillet C: Protocols for an improved detection of point mutations by SSCP. Nucleic Acids Res 19:4009, 1991
17. Landers JE, Haines DS, Strauss JF, George DL: Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745, 1994
18. Mahoney DH, Camitta BM, Leventhal BG, Shuster J, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. Cancer 75:2623, 1995
19. Lauer SJ, Toledano S, Winich N, Munez L, Mahoney D, Pullen J, Steuber CP, Shuster J, Camitta B: A comparison of early intensive methotrexate/mercaptopurine (MTX/MP) vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia (HR-ALL): A Pediatric Oncology Group (POG) randomized phase III study. Proc ASCO 14:342, 1995 (abstract 1030)
20. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancer. J Natl Cancer Inst 84:845, 1992
21. Marks DI, Vonderheid EC, Kurz BW, Bigler RD, Sinha K, Nowell PC, Haines DS: Analysis of p53 and mdm-2 expression in 18 patients with Sezary syndrome. Br J Haematol (in press)
22. Pines J: p21 inhibits cyclin shock. Nature 369:520, 1994
23. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859, 1992
24. Hono Y, Takahashi T, Kuroishi, Hibi K, Suyama M, Niimi T, Shimohata K, Yamakawa K, Nakamura Y, Ueda R, Takahashi T: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1, 1993
25. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HR, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
26. Nylander K, Stenling R, Gustafson H, Zackrisson B, Roos G: p53 expression and cell proliferation in squamous cell carcinomas of the head and neck Cancer 75-87, 1995
27. Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Lai JL, Hecquet B, Coppin MC, Nelkin B, Gosselin B, Fenaux P: Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 13:812, 1995
28. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in B-cell lymphoblastic leukemia: a report on 60 cases. Leukemia 6:42, 1992
29. Crook T, Marston NJ, Sara EA, Voudsen KH: Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817, 1994
30. Hachiya M, Chumakov A, Miller CW, Akashi M, Said J, Koeffler HP: Mutant p53 proteins behave m a dominant negative fashion in vivo. Anticancer Res 14:1853, 1994
31. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827, 1992
32. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el Houseini ME: Induction of p21 (WAF-1/CIP-1) during differentiation. Oncogene 9:3389, 1994
33. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587, 1992
34. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293, 1995
35. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582, 1994